Agreed, but what caught my attention from the announcement was "considers potential corporate partnerships to expedite the commercialisation of its lead compound RECCE® 327 as a potential therapy for drug resistant bacteria and viruses". A partner to fund and expedite the trial process, hopefully this is in the near term, as it saves us from upteen CR's and dilution (a concern of mine). Still feel likes it's going to be long road though....but there'll be numerous chances to top up as the company and its star product, are de-risked. Government rebates and innovation initiatives will only carry RCE so far.
GL longs.
RCE Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)